NUVL insider trading
NasdaqGS HealthcareNuvalent, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Nuvalent, Inc.
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Company website: nuvalent.com
NUVL insider activity at a glance
FilingIQ has scored 933 insider transactions for NUVL since Jun 30, 2015. The most recent filing in our index is dated May 4, 2026.
Across the full history, 3 open-market purchases
and 563 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on NUVL insider trades is 62.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest NUVL Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
13F funds holding NUVL
Frequently asked
- How many insider trades does FilingIQ track for NUVL?
- FilingIQ tracks 933 Form 4 insider transactions for NUVL (Nuvalent, Inc.), covering filings from Jun 30, 2015 onwards. 86 of those were filed in the last 90 days.
- Are NUVL insiders net buyers or net sellers?
- Across the full Form 4 history for NUVL, 3 transactions (0%) were open-market purchases and 563 (60%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does NUVL insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is NUVL in?
- Nuvalent, Inc. (NUVL) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $7.63B.
Methodology & sources
Every NUVL insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.